Enterprise Group

Enterprise Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma. The company focuses on enhancing mucociliary clearance by targeting ion channels to increase hydration and reduce mucus viscosity in the airways. Their lead program, ETD001, is a first-in-class ENaC blocker designed for long-acting effect and improved safety compared to previous generations of the class. By addressing the underlying causes of mucus congestion, Enterprise Therapeutics aims to significantly improve lung function and quality of life for patients with chronic respiratory conditions.